NVDA
NVIDIA
-- 113.760 TSLA
Tesla
-- 272.060 GME
GameStop
-- 28.360 PLTR
Palantir
-- 92.280 AMD
Advanced Micro Devices
-- 110.190 
Watching! Look at date/time!
$HOOKIPA Pharma (HOOK.US)$ HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
16 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
NEW YORK and VIENNA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that the Company will present preclinical data related to the HB-700 program for the treatment of KRAS mutated cancers at the 6thAnnual RAS-Targeted Drug Development Summit being held in Boston, Massachusetts from September 24-26, 2024.
"HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found in pancreatic, colorectal and lung cancers. While a number of KRAS programs are focused on a single mutation, our program is uniquely suited to target the most prevalent KRAS mutations of these cancers in a single therapy," said Mark Winderlich, PhD, Chief Research & Development Officer. "HOOKIPA's approach could enable HB-700 to be a widely used, multi-KRAS therapy. The preclinical dataset has demonstrated safety, induction of target-specific CD8+ T-cells, and target cell killing in several different animal and translational models. With IND clearance, received from the FDA in Q2 2024, HB-700 is a Phase 1 ready asset."
Presentation Details:
• Oral Presentation (Virtual): Development of an Arenavirus-Based Immunotherapy for Treatment of KRAS Mutant Cancer
• Session: Drug Discovery & Preclinical Development
• Presentation Date/Time: Wednesday, September 25, 12:45 to 1:15 PM ET
16 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
NEW YORK and VIENNA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced that the Company will present preclinical data related to the HB-700 program for the treatment of KRAS mutated cancers at the 6thAnnual RAS-Targeted Drug Development Summit being held in Boston, Massachusetts from September 24-26, 2024.
"HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found in pancreatic, colorectal and lung cancers. While a number of KRAS programs are focused on a single mutation, our program is uniquely suited to target the most prevalent KRAS mutations of these cancers in a single therapy," said Mark Winderlich, PhD, Chief Research & Development Officer. "HOOKIPA's approach could enable HB-700 to be a widely used, multi-KRAS therapy. The preclinical dataset has demonstrated safety, induction of target-specific CD8+ T-cells, and target cell killing in several different animal and translational models. With IND clearance, received from the FDA in Q2 2024, HB-700 is a Phase 1 ready asset."
Presentation Details:
• Oral Presentation (Virtual): Development of an Arenavirus-Based Immunotherapy for Treatment of KRAS Mutant Cancer
• Session: Drug Discovery & Preclinical Development
• Presentation Date/Time: Wednesday, September 25, 12:45 to 1:15 PM ET
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment